

NEWS RELEASE

PAUL LUCAS: NEW CHAIRMAN OF RX&D'S BOARD OF DIRECTORS

Ottawa, November 15, 2005 – *Canada's Research-Based Pharmaceutical Companies (Rx&D)* is pleased to announce the appointment of Paul Lucas, President and Chief Executive Officer (CEO) of GlaxoSmithKline Inc., as Chairman of the Board of Directors.

Mr. Lucas is a member of Rx&D's Executive Committee and Board of Directors, and until becoming Board Chairman, fulfilled the role of Chairman of Rx&D's Federal Government Affairs/FPT Relations Standing Committee. He previously served as Rx&D Board Chairman in 1998-1999.

"I am proud to lead an industry of more than 22,000 people who discover and develop new medicines that improve the quality of life for Canadian patients," says Mr. Lucas.

"Canada can, and should, be a global leader in creating new medicines. I encourage the federal government to continue to move forward in their support of intellectual property protection. This is essential in fostering innovation in our industry, and will help us play a vital role in making Canada one of the top five most innovative economies in the world."

In addition to his present responsibilities, Mr. Lucas is the Chairman of the Board of Directors of TM Bioscience, and is a member of the Board of Trustees at Queen's University, where he serves as Chair of the Advancement Committee. He is also a member of the Principal's Advisory Council of the University of Toronto at Mississauga. In 2003, Mr. Lucas served as the Chairman of the United Way Campaign for the Region of Peel, and continues to play an active role in Canada's philanthropic community through IMAGINE.

Mr. Lucas was appointed President and Chief Executive Officer of GlaxoSmithKline in June 2000 and is currently responsible for all pharmaceutical operations in Canada. Having joined Glaxo Canada in September 1986, he was appointed President and Chief Executive Officer in 1994. Prior to joining the company, Mr. Lucas held progressive management positions at Eli Lilly Canada and McNeil Pharmaceutical.

Canada's Research-Based Pharmaceutical Companies (Rx&D) is an association of members dedicated to improving the health of all Canadians. As partner of the health care system, our discoveries help eliminate the need for medical procedures such as surgery, which have a significant impact on patient quality of life and health care budgets. Our community represents more than 22,000 men and women working for over 50 member companies in Canada.

- 30 -

For further information:
François Lessard
Communications
Tel: 613-236-0455